547 results on '"Onar-Thomas, Arzu"'
Search Results
2. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
3. Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Childrens Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials.
4. DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts
5. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors
6. Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
7. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.
8. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042)
9. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
10. Hypogonadism After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy
11. Endocrinopathy After Treatment for Medulloblastoma: Results From the SJMB03 Trial of Risk-Adapted Radiation Therapy
12. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials
13. Unified rhombic lip origins of group 3 and group 4 medulloblastoma
14. Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial
15. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
16. A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors
17. Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single‐institution study with molecular correlation.
18. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
19. Computing Power and Sample Size for the False Discovery Rate in Multiple Applications
20. Real-World Database Studies in Oncology: A Call for Standards
21. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
22. Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study
23. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children’s Oncology Group Study
24. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors
25. Bayesian Adaptive Randomization: Full of Promise With a Helping of Caution
26. Application of the Rotterdam postoperative cerebellar mutism syndrome prediction model in patients undergoing surgery for medulloblastoma in a single institution
27. 1 Ototoxicity and Cognitive Outcomes among Children Treated for Brain Tumors in Infancy
28. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
29. Biomechanical analysis of accurately and carefully placing an aerospace avionics box in restricted space
30. Conformal Radiation Therapy for Pediatric Patients with Low-Grade Glioma: Results from the Children's Oncology Group Phase 2 Study ACNS0221
31. Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma
32. Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
33. Application of the Rotterdam postoperative cerebellar mutism syndrome prediction model in patients undergoing surgery for medulloblastoma in a single institution.
34. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
35. SPCR-08 ACADEMIC READINESS AMONG CHILDREN TREATED FOR BRAIN TUMORS IN INFANCY
36. Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials
37. The effects of different carrying methods on locomotion stability, gait spatio-temporal parameters and spinal stresses
38. Acquisition of Cholangiocarcinoma Traits during Advanced Hepatocellular Carcinoma Development in Mice
39. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors
40. Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium
41. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
42. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome
43. Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy
44. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience
45. The effect of motorcycle helmet fit on estimating head impact kinematics from residual liner crush
46. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
47. Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
48. Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
49. Supplementary Figure from Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
50. Supplementary Data from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.